Sugi Predict

Sugi Predict / Compounds / SCHEMBL330372

SCHEMBL330372

SCHEMBL330372

Fc1ccc2c(c1)CCNC2

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ASIC3 Q9UHC3 4/20 0.60
▸ DRD2 P14416 2/20 0.56
▸ DRD3 P35462 2/20 0.56
▸ PNMT P11086 5/20 0.54
▸ CD44 P16070 1/20 0.54
▸ MAOB P27338 1/20 0.54
▸ HTR2C P28335 2/20 0.51
▸ HTR2A P28223 1/20 0.51
▸ ADRA2A P08913 1/20 0.50
▸ ADRA2B P18089 1/20 0.50
▸ ADRA2C P18825 1/20 0.50
▸ HTR2B P41595 1/20 0.49
▸ MELK Q14680 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1000880 0.98 ASIC3 (0.58) ASIC3DRD2DRD3PNMTCD44
SCHEMBL29741628 0.92 PNMT (0.60) DRD2DRD3PNMTCD44MAOB
SCHEMBL420370 0.92 PNMT (0.60) DRD2DRD3PNMTCD44MAOB
Hydrochloric Acid SCHEMBL999244 0.90 PNMT (0.58) DRD2DRD3PNMTCD44MAOB
Hydrochloric Acid SCHEMBL29586555 0.90 PNMT (0.58) DRD2DRD3PNMTCD44MAOB
SCHEMBL30950592 0.88 ASIC3 (0.47) ASIC3DRD2DRD3PNMTCD44
SCHEMBL1887809 0.88 ASIC3 (0.47) ASIC3DRD2DRD3PNMTCD44
SCHEMBL6951426 0.87 HTR2C (0.61) ASIC3DRD2PNMTHTR2CHTR2A
SCHEMBL107103 0.82 CYP1A2 (0.43) ASIC3PNMTHTR2CHTR2AADRA2A
Hydrochloric Acid SCHEMBL1266812 0.80 CYP1A2 (0.42) ASIC3PNMTHTR2CHTR2AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055343-A Deuterium and aryl amine compounds and uses thereof 泽农医药公司 2026-05-15 — — CN disclosed
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
CN-120157617-A Solid crystalline forms of selective potassium channel modulators 泽农医药公司 2025-06-17 — — CN disclosed
US-12319657-B1 Solid state crystalline forms of a selective potassium channel modulator XENON PHARMACEUTICALS INC. (CA) 2025-06-03 — — US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
CN-119948023-A Regulator containing piperidine polycyclic derivative, preparation method and application thereof 上海翰森生物医药科技有限公司 2025-05-06 — — CN disclosed
WO-2025064502-A1 DEUTERIUM AND ARYL AMINE COMPOUNDS AND USES THEREOF XENON PHARMACEUTICALS INC. (CA) 2025-03-27 — — WO disclosed
EP-4523687-A2 SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR Xenon Pharmaceuticals Inc. (CA) 2025-03-19 — — EP disclosed
WO-2025038933-A1 ARYL AMINE COMPOUNDS AND USES THEREOF XENON PHARMACEUTICALS INC. (CA) 2025-02-20 — — WO disclosed
CN-119100981-A Solid crystalline forms of selective potassium channel modulators 泽农医药公司 2024-12-10 — — CN disclosed
WO-2008040492-A1 SUBSTITUTED SULFONAMIDE DERIVATIVES Grünenthal GmbH (DE) 2008-04-10 — — WO disclosed
WO-2008024398-A2 DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2008-02-28 — — WO disclosed
WO-2008024398-A2 DERIVATIVES OF 4-(N-AZACYCLOALKYL) ANILIDES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2008-02-28 — — WO disclosed
EP-1749007-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION Intermune, Inc. (US) 2007-02-07 — — EP disclosed
EP-1680137-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION Intermune, Inc. (US) 2006-07-19 — — EP disclosed
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication HOFFMANN-LA ROCHE INC. 2005-12-01 — — US disclosed
WO-2005095403-A2 MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2005-10-13 — — WO disclosed
WO-2005037214-A2 MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION INTERMUNE, INC. (US) 2005-04-28 — — WO disclosed
CN-1278260-A Aminomethyl-benzo [a] quinolizidine derivatives, prepns. and therapeutic applications for neurodegenrative diseases PF MEDICAMENT (FR) 2000-12-27 — — CN disclosed
US-4963563-A TREATING GLAUCOMA; INHIBITORS OF ALPHA-2-ADRENERGIC RECEPTORS ABBOTT LABORATORIES (US) 1990-10-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 ASIC3 3751/4885DRD2 4732/4885DRD3 4556/4885
US-20050267018-A1 Macrocyclic compounds as inhibitors of viral replication EIF2AK2, HAVCR2, ZC3HAV1 ASIC3 4592/4885DRD2 4860/4885DRD3 4852/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 ASIC3 3751/4885DRD2 4732/4885DRD3 4556/4885
US-12319657-B1 Solid state crystalline forms of a selective potassium channel modulator KCNQ2, KCNN2, KCNN3 ASIC3 248/4885DRD2 2940/4885DRD3 3437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.